What is Centogene?
Centogene N.V. operates as a specialized provider of pharmaceutical solutions and diagnostic testing, with a footprint extending across Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company is recognized for its data-driven approach to rare disease diagnostics, utilizing advanced technologies such as the CENTOGENE MOx 2.0 multiomic solution. By integrating DNA sequencing, biochemical testing, and RNA sequencing, the firm provides critical insights to physicians and pharmaceutical partners. Furthermore, its cloud-based infrastructure, including CentoCloud and the FilterTool application, enables laboratories to interpret genomic variants with high precision, thereby accelerating the identification of potential treatment pathways for patients with high unmet medical needs.
How much funding has Centogene raised?
Centogene has raised a total of $146M across 4 funding rounds:
Series A
$28M
Stock Offering
$56M
Debt
$45M
Share Placement
$17M
Series A (2017): $28M with participation from Careventures, Deutsche Private Equity, and TVM Capital
Stock Issuance/Offering (2019): $56M led by Undisclosed
Debt (2022): $45M supported by Oxford Finance
Share Placement (2022): $17M featuring Deutsche Private Equity, Careventures, and TVM Capital
Key Investors in Centogene
Deutsche Private Equity
DPE Deutsche Private Equity is an independent German investment firm focusing on mid-sized companies in the German-speaking region that demonstrate long-term growth potential.
Careventures
Careventures is an independent pan-European private equity firm dedicated to improving healthcare through smart investments and partnerships with middle-market healthcare companies.
TVM Capital
TVM Capital Life Science is a transatlantic venture capital firm that provides capital and expertise to support the development of breakthrough therapies and medical products.
What's next for Centogene?
With the support of its recent strategic financing, Centogene is well-positioned to expand its diagnostic reach and enhance its portfolio of Next Generation Sequencing (NGS) assays. The company's roadmap likely involves deepening its integration within the pharmaceutical R&D ecosystem, where its proprietary data assets serve as a catalyst for drug discovery and clinical trial optimization. As the firm navigates the complexities of the global healthcare market, the focus will remain on scaling its digital health platforms and maintaining its leadership in the rare disease diagnostic sector. This strategic deployment of capital is expected to drive long-term value by fostering innovation in personalized medicine and improving patient access to life-saving therapies.
See full Centogene company page
